Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Acupuncture-Moxibustion and Tuina, Qilu Hospital of Shangdong University, Jinan, Shangdong 250012, PR China.
Biomed Pharmacother. 2021 Jun;138:111426. doi: 10.1016/j.biopha.2021.111426. Epub 2021 Mar 21.
WangShiBoChiWan (WSBCW) is a commonly used Chinese herbal medicine for the treatment of functional gastrointestinal disorders. However, its preclinical efficacy and the mechanisms of action have not been adequately studied. The goals of this study were to evaluate the effects of WSBCW on gastrointestinal health and modulation of related biomarkers. Female C57BL mice were randomly assigned into one of the experimental groups consisting of the control, drug controls, and WSBCW at 40, 120, and 360 mg/kg BW. Whole gut transit, small intestinal motility, and intestinal barrier permeability were determined. The castor oil-induced diarrhea mouse model was used to determine the effect of WSBCW on the diarrhea type of irritable bowel syndrome (IBS-D). WSBCW increased whole gut transit and intestinal motility, improved intestinal permeability in healthy animals and alleviated diarrhea symptoms in IBS-D mice. WSBCW upregulated intestinal junction proteins, increased the abundance of Bifidobacterium genus, Desulfovibrio genus and inhibited Bacteroides fragillis group in the gut microbiota, increased intestinal villi lengths, and decreased blood levels of inflammatory cytokines. Our study provided preclinical evidence to verify the effectiveness of WSBCW in gastrointestinal health and elucidate mechanistic insights. The results warrant further investigations to evaluate the therapeutic efficacy of WSBCW on gastrointestinal disorders, such as IBS and IBD.
王氏保赤丸（WSBCW）是一种常用于治疗功能性胃肠疾病的中药。然而，其临床前疗效和作用机制尚未得到充分研究。本研究旨在评估 WSBCW 对胃肠道健康的影响及其相关生物标志物的调节作用。将雌性 C57BL 小鼠随机分为对照组、药物对照组和 WSBCW 组（40、120 和 360mg/kgBW）。测定全肠道转运、小肠动力和肠道屏障通透性。使用蓖麻油诱导的腹泻小鼠模型，观察 WSBCW 对 IBS-D 腹泻型的影响。WSBCW 可增加全肠道转运和肠道动力，改善健康动物的肠道通透性，缓解 IBS-D 小鼠的腹泻症状。WSBCW 上调肠道连接蛋白，增加肠道微生物群中双歧杆菌属、脱硫弧菌属的丰度，抑制脆弱拟杆菌群，增加肠绒毛长度，降低炎症细胞因子的血液水平。本研究为 WSBCW 在胃肠道健康方面的有效性提供了临床前证据，并阐明了其作用机制。这些结果值得进一步研究，以评估 WSBCW 对胃肠道疾病（如 IBS 和 IBD）的治疗效果。
